Clinical Trial Update | FDA Early Feasibility Study Completion
I am pleased to share a clinical update regarding the Early Feasibility Study (EFS) evaluating the Inner Cosmos minimally invasive […]
Uncategorized
Inner Cosmos Appoints John Freund to Board of Directors and Greg Schulte as Advisory CTO to Advance Psychiatric BCI for Depression
Inner Cosmos Inner Cosmos, a neurotechnology company pioneering psychiatric treatment with a minimally invasive BCI for refractory depression, today announced
Clinical Study Update | Q2 2025
Interim 36-Month Outcomes from Inner Cosmos’ Psychiatric Neurostimulation Study in Treatment-Resistant Depression Inner Cosmos is pleased to share new interim